Bayesian Capital Management’s GeneDx Holdings WGS Stock Holding History

Bayesian Capital Management’s Portfolio WGS Stock Details WGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-9,700	Closed	-$1.05M	–	547
2025 Q3	$1.05M	Buy	+9,700	New	+$1.06M	0.21%	154
2025 Q2	–	Sell	-2,600	Closed	-$230K	–	902
2025 Q1	$230K	Buy	+2,600	New	+$226K	0.04%	453
2023 Q2	–	Sell	-768	Closed	-$9.25K	–	1091
2023 Q1	$9.25K	Sell	768 -315	-29%	-$4.2K	﹤0.01%	743
2022 Q4	$9.43K	Buy	+1,083	New	+$23.9K	﹤0.01%	733

Other funds holding WGS

Corvex Management New York $3.27B AUM 38.53% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

SPPAM

Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bayesian Capital Management's WGS Position: Q4 2025 in Review

Bayesian Capital Management sold out of GeneDx Holdings (WGS) in Q4 2025, closing a stake of 9,700 shares — an estimated $1.05M sold.

Bayesian Capital Management first reported a position in WGS in Q4 2022 and held it in 4 quarters. The position peaked at $1.05M in Q3 2025. 286 funds tracked by Wall St. Rank hold WGS as of Q4 2025.

Bayesian Capital Management reported no remaining GeneDx Holdings position as of Q4 2025 after selling out during the quarter.
Bayesian Capital Management sold 9,700 GeneDx Holdings shares in Q4 2025, an estimated $1.05M.
Bayesian Capital Management first reported a position in GeneDx Holdings in Q4 2022 and held it in 4 quarters.
Bayesian Capital Management's GeneDx Holdings position peaked at $1.05M in Q3 2025.
286 funds tracked by Wall St. Rank held GeneDx Holdings as of Q4 2025.

Based on Bayesian Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.